Antibiotic Treatment for Klebsiella Infections
For non-ESBL-producing Klebsiella, use third-generation cephalosporins or fluoroquinolones; for ESBL-producing strains, carbapenems remain the standard, but newer beta-lactam/beta-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) are superior for carbapenem-resistant strains.
Non-ESBL Klebsiella Infections
For community-acquired or hospital-acquired Klebsiella infections without ESBL production:
- Third-generation cephalosporins (ceftriaxone, cefotaxime) are first-line
- Fluoroquinolones (ciprofloxacin, levofloxacin) are effective alternatives if susceptible 1
- Aminoglycosides can be used in combination for severe infections
ESBL-Producing Klebsiella
Standard Therapy
Carbapenems (ertapenem, meropenem, imipenem) are the established first-line agents for ESBL-producing Klebsiella 2. The evidence shows no significant mortality difference between different carbapenems, with ertapenem demonstrating similar or better outcomes compared to imipenem/meropenem for bloodstream infections 2.
Carbapenem-Sparing Alternatives
When carbapenem stewardship is needed or for specific clinical scenarios:
Fluoroquinolones (ciprofloxacin or levofloxacin): If in vitro susceptible, these can serve as carbapenem-sparing alternatives. A propensity-matched study showed 30-day mortality of 8.3% with fluoroquinolones versus 29.2% with carbapenems (p=0.05), with fluoroquinolone therapy being protective (OR 0.18, p=0.04) 1. This applies specifically to bloodstream infections when the isolate tests susceptible.
High-dose amoxicillin-clavulanate: For urinary tract infections specifically, starting with 2875mg amoxicillin/125mg clavulanate twice daily showed zero therapeutic failures in a 2023 study of recurrent UTIs 3. This is an oral option for outpatient management of ESBL UTIs.
Cefepime: May be considered for ESBL infections, though evidence is limited and older 4. Use cautiously and only when susceptibility is confirmed.
Tigecycline: Demonstrates 92.5% susceptibility against Klebsiella strains with MICs 0.19-4 μg/mL 5, 6. Effective for intra-abdominal and complicated skin infections, but avoid for bloodstream infections due to low serum levels.
Carbapenem-Resistant Klebsiella (CRE)
KPC-Producing Strains
Ceftazidime-avibactam or meropenem-vaborbactam are strongly recommended as first-line therapy 7. The evidence hierarchy:
Ceftazidime-avibactam: 28-day mortality of 18.3% versus 40.8% with other active agents (p=0.005) in propensity-matched analysis 7. Also safer than colistin with lower nephrotoxicity risk.
Meropenem-vaborbactam: Showed higher clinical cure rates and decreased mortality versus best available therapy in the TANGO II trial 7. Preferred for pneumonia due to superior lung penetration (63% for meropenem, 65% for vaborbactam in epithelial lining fluid) 7.
Critical caveat: Ceftazidime-avibactam resistance is emerging (0-12.8% prevalence) due to KPC variants (D179Y mutations in blaKPC-3) 7, 8. When this occurs, meropenem-vaborbactam remains active 7.
- Imipenem-relebactam and cefiderocol: Potential alternatives but limited clinical data for KPC infections 7
OXA-48-Producing Strains
Ceftazidime-avibactam should be first-line (conditional recommendation, very low certainty evidence) 7.
Pan-Drug Resistant Klebsiella
When all standard options fail or are contraindicated:
- Colistin remains an option but carries significant nephrotoxicity risk
- Oral doxycycline 100mg twice daily plus rifampin 600mg once daily: A 2026 case report demonstrated efficacy as salvage therapy when colistin caused acute kidney injury 9. This is a low-cost option for highly resistant strains when standard therapies are unavailable.
Practical Algorithm
- Obtain susceptibility testing immediately - treatment depends critically on resistance pattern
- Non-ESBL: Use cephalosporins or fluoroquinolones
- ESBL-producing:
- Severe infections → Carbapenems
- UTI only → Consider high-dose amoxicillin-clavulanate orally
- Fluoroquinolone-susceptible bloodstream infection → Fluoroquinolones acceptable
- KPC-producing CRE:
- Pneumonia → Meropenem-vaborbactam preferred
- Other sites → Ceftazidime-avibactam or meropenem-vaborbactam
- Pan-resistant: Colistin or doxycycline-rifampin combination
Major pitfall: The post-COVID era has seen increased ceftazidime-avibactam resistance (1.1% in 2021 to 2.7% in 2022), often with cross-resistance to other last-line agents 8. Always verify susceptibility to newer agents rather than assuming activity based on resistance mechanism alone.